Filing Flows › Comparisons › ASMB vs OCUL
Assembly Biosciences vs Ocular Therapeutix: ASMB and OCUL compared
Assembly Biosciences is the larger company: $13.4M of revenue in its latest quarter (Q2 2026) against $12.9M for Ocular Therapeutix (Q3 2026). Assembly Biosciences is growing faster (+39% against -12% a year earlier). Assembly Biosciences is more profitable, with an operating margin of -47.4% against -760.1%.
Where the money goes: ASMB and OCUL
Assembly Biosciences (ASMB) · Q2 2026
Assembly Biosciences, Q2 2026: revenue $13.4M (+39% year over year), operating margin -47.4%, net loss $3.9M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
Ocular Therapeutix (OCUL) · Q3 2026
Ocular Therapeutix, Q3 2026: revenue $12.9M (-12% year over year), operating margin -760.1%, net loss $94.8M, operating cash flow −$65.6M. The chart follows the revenue to costs, profit and cash.
| Assembly Biosciences (ASMB) | Ocular Therapeutix (OCUL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $13.4M | $12.9M |
| Revenue growth, Y/Y | +39% | -12% |
| Operating margin | -47.4% | -760.1% |
| Net earnings | −$3.9M | −$94.8M |
| Net margin | -28.8% | -736.2% |
| Operating cash flow | −$15.5M | −$65.6M |
Questions
Which is bigger, Assembly Biosciences or Ocular Therapeutix?
Assembly Biosciences is the larger company: $13.4M of revenue in its latest quarter (Q2 2026) against $12.9M for Ocular Therapeutix (Q3 2026).
Is Assembly Biosciences or Ocular Therapeutix growing faster?
Assembly Biosciences is growing faster (+39% against -12% a year earlier).
Which is more profitable, Assembly Biosciences or Ocular Therapeutix?
Assembly Biosciences is more profitable, with an operating margin of -47.4% against -760.1%.
More: Assembly Biosciences earnings · how Assembly Biosciences makes money · Ocular Therapeutix earnings · how Ocular Therapeutix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.